Natalie Keirstead

Company: Mersana Therapeutics

Job title: Senior Vice President - Nonclinical Development

Seminars:

Improving Predictability – Deciding on the Best in vivo Model in Order to Replicate Toxicities Clinically 9:00 am

Optimizing an ADC platform to minimize platform off-target toxicity Comparing two NaPi2b ADCs produced using two different platforms, improving safety and efficacy both pre-clinically and clinically Leveraging the rat versus NHPs, for investigative mechanistic studiesRead more

day: Conference Day 1